18598-63-5 99%

Ajitha prodrug has established a simple, yet powerful chemistry platform enabling best-in-class payload diversities in Tubulysins, Auristatins, and various other therapeutic payloads. Ajitha Prodrug is specialized in development of optimized linkers, and suitable conjugation strategies to meet wide ranging needs of research clients. We also pioneer in the small molecule and peptide drug conjugations for targeted delivery studies.

We want to be a “Responsible, Disruptive and Leading” producer of “Novel Tubulysin Derivatives and Adjacencies” in the fast-growing Antibody Drug Conjugates (ADC) segment.

Enabling Oncological treatment to be “Affordable while upholding the core Medical Ethical Pillars”. 

Our core portfolio and research focus is tubulysin toolbox through diverse chemistry platform which has the game changer payloads for ADCs. We are also committed towards linker technologies and small molecule/peptide drug conjugates.